Deletions at 16p13.11 are associated with schizophrenia, mental retardation, and most recently idiopathic generalized epilepsy. To evaluate the role of 16p13.11 deletions, as well as other structural variation, in epilepsy disorders, we used genome-wide screens to identify copy number variation in 3812 patients with a diverse spectrum of epilepsy syndromes and in 1299 neurologically-normal controls. Large deletions (> 100 kb) at 16p13.11 were observed in 23 patients, whereas no control had a deletion greater than 16 kb. Patients, even those with identically sized 16p13.11 deletions, presented with highly variable epilepsy phenotypes. For a subset of patients with a 16p13.11 deletion, we show a consistent reduction of expression for included genes, suggesting that haploinsufficiency might contribute to pathogenicity. We also investigated another possible mechanism of pathogenicity by using hybridization-based capture and next-generation sequencing of the homologous chromosome for ten 16p13.11-deletion patients to look for unmasked recessive mutations. Follow-up genotyping of suggestive polymorphisms failed to identify any convincing recessive-acting mutations in the homologous interval corresponding to the deletion. The observation that two of the 16p13.11 deletions were larger than 2 Mb in size led us to screen for other large deletions. We found 12 additional genomic regions harboring deletions > 2 Mb in epilepsy patients, and none in controls. Additional evaluation is needed to characterize the role of these exceedingly large, non-locus-specific deletions in epilepsy. Collectively, these data implicate 16p13.11 and possibly other large deletions as risk factors for a wide range of epilepsy disorders, and they appear to point toward haploinsufficiency as a contributor to the pathogenicity of deletions.
Introduction
Although common SNPs have been shown to play at most a modest role in most neuropsychiatric diseases, a growing body of evidence connects large deletions and duplications, or copy number variants (CNVs), to schizophrenia, autism, and mental retardation. [1] [2] [3] [4] [5] Recently, deletions at 15q13.3 and 16p13.11, previously implicated in schizophrenia 2 and mental retardation, 6 have now been associated with idiopathic generalized epilepsy. 7, 8 These findings add epilepsy to the growing list of neuropsychiatric conditions with overlapping susceptibility conferred by copy number variation.
Here, we report a genome-wide screen evaluating the role of large, rare CNVs in patients affected with a wide range of seizure disorders, including both partial and generalized seizure disorders. We also explore possible mechanisms of pathogenicity for large deletions in neuropsychiatric disease.
Subjects and Methods

Subjects
Patients with either focal (> 90%) or generalized epilepsy were drawn from four sites making up the EPIGEN Consortium (Brussels, . All patients were asked to participate in a study investigating the genetics of epilepsy during routine clinical appointments at each site, in accordance with institutional standards. All patients had a definite diagnosis of epilepsy according to International League Against Epilepsy (ILAE) definitions. Seizure types and epilepsy syndromes were classified according to the ILAE classifications. DNA was extracted from primary (untransformed) cells from either a blood (n ¼ 3729) or brain (n ¼ 63) sample. No recruited patients with neuropsychiatric disease and/or mental retardation were excluded if they met the criteria of having a genetically unexplained seizure disorder. Information about family history was provided by the patient, but blood samples for DNA were obtained only from consenting family members if the primary patient had a putative epilepsy-associated deletion and the individual consented to the follow-up investigations.
For comparison, we used controls from Finland and Switzerland who had no neuropsychiatric condition (n ¼ 546). In addition, we evaluated 755 cognitively normal control subjects who had taken part in the Genetics of Memory study at Duke University and had undergone cognitive testing. These subjects were used to assess the frequency of epilepsy-associated deletions in controls and to assess the effects of epilepsy-associated CNVs on cognitive function. DNA from control subjects was obtained from blood (n ¼ 52) or saliva (n ¼ 1247). Controls used in this study partially overlap controls used in the Need et al. 2009 schizophrenia (SCZD [MIM 181500]) study. 2 A total of 753 controls overlapped with this study; there were 546 unique controls evaluated here and 840 unique neuropsychiatrically normal controls evaluated in Need et al. 2 In some cases, patients were recontacted with a request for additional blood samples from family members, blood samples for expression assessments, and additional blood samples for DNA when necessary. We were successful in obtaining additional samples only in a subset of patients. All phenotypic data and samples were collected in accordance with the ethical standards set forth by the Duke University Institutional Review Board, Durham 
Genome-wide Genotyping
DNA from all individuals were genotyped on the Illumina Human 610-Quad genome-wide genotyping array, with the exception of a subset run on other chips, including HumanHap 1M (n ¼ 4), HumanHap 550K (n ¼ 131), and HumanHap 317K (n ¼ 47). All samples were genotyped in the Institute for Genome Sciences & Policy Genotyping Facility, and quality control measures were standardized across all batches.
CNV Calling
The CNV calls were generated with the PennCNV software (version 2008 June 26), with the use of the log R ratio (LRR) and B allele frequency (BAF) for all SNPs and CNV probes included on the genotyping chips. Standard PennCNV quality control checks were used for excluding unreliable samples, including LRR standard deviation (SD) greater than 0.28, BAF median greater than 0.55 or less than 0.45, BAF drift greater than 0.002, or a waviness factor of greater than 0.04 or less than À0.04. Individual CNVs were excluded if the PennCNV-generated confidence score was less than 10, if they were called on the basis of fewer than ten SNPs or CNV probes, if the CNV spanned a centromere, and, finally, if the CNVs overlapped at least 50% with regions previously described as being prone to false positives due to somatic mutations. 2 Deletions greater than 1 Mb and specific regions associated with epilepsy were visually inspected in Illumina Beadstudio for calling accuracy. Specifically, in cases of a subject having two or more CNVs called within 1 Mb of each other, the uncalled region was inspected for the genotyping quality. If only SNPs that failed genotyping quality control were used to establish a break in the CNV, it was assumed to be continuous.
Confirmation of a Subset of Deletions
Deletions were confirmed in a subset of patients via comparative genomic hybridization (CGH) (Roche Nimblegen, HG18 WG Tiling CGH 2.1M v2). Deletions at 16p13.11 were confirmed via quantitative real-time PCR amplification of genomic DNA. Standard protocol was used for amplificiation, with b-globin used as an internal reference. In brief, multiplex 10 curve was constructed for b-globin and the locus within 16p13.11 on the basis of the number of cycles needed to achieve a threshold fluorescence for fixed amounts of DNA from subjects with two copies 16p13.11 (based on PennCNV calls), ranging from 0.25 to 200 ng. Relative copy number in the test sample was estimated by extrapolating from the standard curves an estimated DNA amount at each locus on the basis of the number of cycles needed to reach the defined threshold for that sample, then taking a ratio (16p13.11/b-globin). An average ratio, with an associated coefficient of variation between replicates of less than 25%, of greater than 0.25 and less than 0.75 was considered to be a single-copy deletion at 16p13.11. Correspondingly, a twocopy state at the 16p13.11 locus was called if the ratio was greater than 0.75 and less than 1.25.
Expression Analyses in Blood Samples
Blood samples from a subset of patients with epilepsy-associated deletions were studied for effects on gene expression. Blood was collected in Tempus tubes (Applied Biosystems) and extracted via a standard protocol. Quality of RNA was assessed on an Agilent Bioanalyzer. Gene transcript levels were estimated with Illumina Human HT-12 v3 microarrays (standard protocols). Data were normalized via robust spline normalization in R (v2.8.0). Only transcripts whose normalized expression in a set of n ¼ 8 controls exceeded the mean normalized expression values across all transcripts evaluated on the array were included in this analysis, ensuring the highest sensitivity for detection of an effect. Data generated in this experiment is publically available through Gene Expression Omnibus (accession number GSE20977).
Deletion Inheritance
When available, blood samples were obtained from family members, and DNA was extracted and analyzed on the Illumina 610-Quad genotyping array. The relevant regions were visually inspected (in Beadstudio) and statistically assessed in PennCNV for ascertainment of copy number status. Relationships were confirmed with the use of genome-wide SNP-genotyping data.
Capture and Next-Generation Sequencing of the 16p13. Table 1 ). Consistent with previous reports, this patient has a diagnosis of juvenile myoclonic epilepsy (Table S1 , available online), a form of idiopathic generalized epilepsy. The absence of 15q13.3 deletions in any of the more than 3000 focal epilepsy patients suggests that its involvement in epilepsy disorders is specific to generalized forms, despite the fact that deletions in this region have been associated with nonspecific effects in neuropsychiatric disease risk. 3, 7, 12 At the second epilepsy-risk locus, 15q11.2, 8 we observed 24 patients and three controls with a deletion larger than 300 kb (one-sided Fisher's exact test, p ¼ 0.06). Two additional cases and three controls had smaller deletions in the region (< 100 kb). Two of the 24 patients (~8%) with a deletion greater than 300 kb in the previously reported risk region had a diagnosis of generalized epilepsy, which is approximately equal to the percentage of patients with generalized epilepsy disorders in the cohort studied. In our analysis, this region does not appear to be clearly associated with partial or generalized epilepsy. At the epilepsy-associated 16p13.11 locus, we found 23 patients with deletions greater than 100 kb in the region, whereas the largest deletion in controls in this region is 16 kb (Figure 1 , one-tailed Fisher's exact test, p ¼ 0.001). Although the deletions in epilepsy patients apparently vary in size, all but three cover a core set of seven genes, including NDE1 (MIM 609449, Figure 1 ), a gene with suspected involvement in human cortical development. 13 Interestingly, we do not see any straightforward phenotypic similarities within the set of patients with 16p13.11 deletions, even among identically sized deletions (Table 2) , including instances of both partial and generalized epilepsy. We also see no increased frequency of psychiatric illness in patients with 16p13.11 deletions, though such an increase might have been expected given the reported role of this deletion in schizophrenia.
2 Psychiatric phenotypes were observed in only four out of 23 patients, which does not exceed the rate of psychiatric comorbidities in the general epilepsy patient population. 14 All patients with a 16p13.11 deletion were adults (>18 yrs of age). Finally, 16p13.11 deletions have previously been associated with mental retardation or multiple congenital abnormalities (MR/MCA), with epilepsy reported in approximately 25% of MR/MCA patients. 6 Although some of the patients have the clinical impression of lower than average intelligence quotients and dysmorphism (Table 2) , none have MR/MCA.
Confirmation of 16p13.11 Deletions
The DNA from one patient with a 16p13.11 deletion was analyzed via CGH ( Figure 2A ). The deletion was confirmed on the CGH array; however, the deletion boundaries were found to be larger ( Figure 2B ) and by directly confirming the overall association statistics for the 16p13.11 region via quantitative real-time PCR in genomic DNA ( Figure 2C ).
Inheritance Patterns of 16p13.11 Deletions
We also investigated inheritance patterns for two individuals carrying 16p13.11 (n ¼ 2) deletions by evaluating the CNV status at 16p13.11 in trios involving both parents of the proband. In one trio the deletion was de novo, whereas for the other proband the deletion was inherited from the mother ( Table 2 ). In addition to the two trios, we also observed two other maternally inherited deletions at 16p13.11 in probands for which only the maternal sample was available ( Table 2 ). In the three cases of inherited 16p13.11 deletions, the parent carriers are unaffected by epilepsy, but no neuropsychiatric testing was carried out on these individuals.
Mechanistic Evaluation of 16p13.11 Deletions Expression Consequences of 16p13.11 Deletions in Lymphocytes For seven of the 23 patients with 16p13.11 heterozygous deletions, we evaluated the effect of the deletion on gene expression of genes included in and nearby the deletion in lymphocytes. We extracted RNA from whole-blood samples of patients with deletions and measured transcriptome-wide expression. We evaluated two groups of genes in this analysis: (1) all genes within 1 Mb of the PennCNV-inferred deletion boundary but not included within it (''nearby'' genes), and (2) genes included in each deletion (genes that are partly or entirely deleted).
We used control samples with no 16p13.11 deletion (n ¼ 8) to calculate SD for the distribution of gene expression for all highly expressed (expressed at level greater than the control group average) ''nearby'' and ''included'' genes for each deletion. We then determined, for each nearby and included transcript, the distance from the mean in SD units. All three highly expressed transcripts included within the PennCNV-estimated boundaries show a clear reduction in expression: 
Screen for Recessive Mutations on the Homologous Chromosome
We next sought to identify mutations present on the homologous region of the intact chromosome that might act as recessive risk factors for epilepsy with effects that are ''unmasked'' by the deletion. We designed a hybridization-based capture experiment that enriched for 2.9 Mb within a stretch of 3.3 Mb, corresponding to~1 Mb surrounding the outermost PennCNV-estimated boundaries of deletions observed in the 16p13.11 region, large intergenic regions excluded (Figure 4 ). We then isolated this sequence in ten individuals of European ancestry with deletions ( Figure 4 , Table 2 ) and sequenced the result in a single lane per individual on an Illumina Genome Analyzer. The 2.9 Mb of captured sequence was sequenced across all individuals at an average read depth of 50 (averages within individuals ranged between 36 and 78), with greater than 5-fold coverage for at least 93% of the sequenced region in each subject. For CCDS (Consensus CoDing Sequence, National Center for Biotechnology Information [NCBI]) genes, 96 5 1% of bases included within exons were covered at least 5-fold, compared to < 0.1% bases covered in exons not targeted in the capture. We then identified all putative functional single-nucleotide variants (SNVs) and indels (nonsynonymous, protein-truncating, or splice-site variants) within the patient-specific PennCNV-estimated deletion boundaries. We identified in total 12 SNVs and no indels meeting the functional criteria. We then evaluated the homozygote frequency of these 12 variants in controls by using both the HapMap CEU population (Utah residents with ancestry from northern and western Europe) and a set of 13 samples that have been whole-genome sequenced in our lab for other projects. We excluded a variant as a candidate for conferring epilepsy risk in homozygote (or hemizygote) form if its homozygote frequency in the HapMap CEU population exceeded 5% or if two or more homozygotes were observed in the control individuals for which whole-genome sequence was available. . The latter two variants were observed in the same subject and were not considered likely candidates. The MPV17L splice-site variant (rs72774859), however, was observed in three subjects with a consistent diagnosis of temporal lobe epilepsy with secondary generalized tonic-clonic seizures (marked on Table 2 ). We therefore genotyped this SNV in the remaining 13 patients harboring a 16p13.11 deletion, as well as in 2997 epilepsy cases lacking a deletion of 16p13.11 and in 1801 nonepileptic controls. No additional patients with a 16p13.11 deletion carried the variant on the intact homolog. We observed five homozygotes among the epilepsy cases (including two with an incongruous phenotype) and two homozygotes within the nonepileptic controls. The SNV in ABCC1 (rs45511401) was also genotyped in the larger cohort and was likewise observed in homozygote form in neuropsychiatrically normal controls. Collectively, these data provide no evidence for the unmasking of functional, recessive variants contributing either to the pathogenicity or to the pleiotropic effects of deletions at chromosome 16p13.11.
Enrichment of Large Heterozygous Deletions in Epilepsy Patients
A total of six of the 23 16p13.11 deletions were larger than 1 Mb ( Additional follow-up analyses of these deletion regions, including CGH confirmation ( Figure S1 ), detailed phenotypes of affected patients (Table S1 ), evaluation of deletion acquisition in a subset of patients (Table S2) , and expression changes associated with the deletions (Figure S2) , are provided online.
Genome-wide Screen for Locus-Specific CNV Associations To detect smaller CNVs that associate with epilepsy susceptibility or broad categories of epilepsy subtypes, including partial epilepsy, generalized epilepsy, or temporal lobe epilepsy, we calculated the frequency of deletions (copy number < 2) and duplications (copy number > 2) in 3812 patients with the epilepsy phenotype, and we compared it to the frequency in neurologically normal controls (n ¼ 1299). The frequency was calculated at each unique start and stop site for CNVs that met all of the defined quality control measures (defined in Subjects and Methods). Each site was assessed for a difference in frequency between groups with the use of a permutation-based Fisher's exact test in PLINK. 24 Using this approach, we detected no locusspecific associations after correcting for multiple testing (> 32,000 tests).
Evaluation of CNV Burden in Epilepsy Patients
Finally, given recent reports suggesting that CNV burden influences other neuropsychiatric diseases, 4, 25 we also evaluated patterns of CNVs in epilepsy patients and controls. The results showed no overall differences in CNV burden, average number of genes within or disrupted by CNVs, or enhanced presence of rare gene-disrupting CNVs as defined previously for schizophrenia. 4 
Discussion
Despite the increasing reports of associations of CNVs with neurological, psychiatric, and developmental disorders, very little is known about the functional mechanisms that result in disease susceptibility. Even more puzzling is the increasing evidence for complex and highly differential phenotypic consequences associated with variants in this class. Pathogenicity, as well as the pleiotropic consequences of CNVs in neuropsychiatric disease, must be due to haploinsufficiency, chromatin disruption leading to diffuse expression changes in the genome, unmasking of a recessive mutation on the intact stretch of homologous chromosome (previously suggested in 1 ), modification of germline or somatic mutations, epigenetic or environmental modifiers, or a combination of two or more of the above possible mechanisms. Individuals with deletions (indicated by the blue bars marking the locations of patient-specific deletions) were selected for a hybridization-based capture and next-generation sequencing experiment in which the intact homologous stretch of chromosome corresponding the deleted segment was sequenced in order to screen for pathogenic recessive mutations that may contribute to the risk associated with the deletion. The average read depth averaged across all ten subjects at each base is shown, and purple bars below mark the regions targeted in the hybridization-based capture. It is a priority for the field to develop systematic approaches to evaluate these and other possible models of pathogenicity. As a first step toward this, we have developed data addressing a subset of these mechanisms in reference to 16p13.11 deletions, which we now clearly associate with a wide spectrum of epilepsy disorders. Specifically, we find a clear reduction of gene expression for included genes, but no systematic effects for genes near the deleted locus (Figure 3) that might indicate an effect on chromatin structure. In addition, at 16p13.11 we find no obvious deleterious recessive variants on the intact homologous chromosome in ten of the patients carrying the deletion. For the 16p13.11 deletion, at least, it therefore does not appear that unmasking of deleterious recessive mutations is a major component of pathogenicity. Collectively, these data seem to point tentatively toward haploinsufficiency of one or more included genes as a mechanism of pathogenicity. However, we note that the model of haploinsufficiency alone would seem unable to explain the variable presentation of deletions at 16p13.11 and those observed in other regions (1q21.1 1 and 15q13.3 3, 7, 12 ). Thus, even if haploinsufficiency is the correct model, it still requires other modifiers to influence the precise disease presentation. In summary, this work suggests that 16p13.11 deletions affect approximately 0.6% of epilepsy patients and that the 16p13.11 deletion is the most prevalent single genetic risk factor for overall seizure susceptibility identified to date. We also identified a number of genic regions that appear to carry epilepsy-associated deletions and warrant detailed evaluation as implemented here for 16p13.11 deletions. Unraveling the interplay of functional and phenotypic consequences of these large deletions will provide novel insights into epilepsy pathophysiology and contribute to an understanding of the complex genetic architecture and phenotypic diversity within epilepsy and, likely, other neuropsychiatric diseases.
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